Before the first invoice comes the first decision: how do you actually enter? Distributor, branch, or your own GmbH — each opens and closes different doors later. This is the map for choosing your entry mode, not the day-to-day of selling.
Entering Germany starts with a strategic choice of entry mode — sell through a distributor, open a branch (Zweigniederlassung), or set up your own company (GmbH). The right answer depends on control, speed, cost, tax and how regulated your product is. Pick the mode first; the sales channels, distribution and reimbursement work comes after, and is covered separately. In regulated life sciences the structure choice is heavier, because your local entity often carries regulatory responsibility.
Most entry mistakes aren't legal — they're strategic. Companies pick a structure by habit, then discover it blocks the channel or tender they needed.
Germany is Europe's largest economy and a demanding, quality-driven market. Getting in is rarely about whether you can — it's about choosing the entry mode that fits your ambition, budget and product. That decision shapes everything downstream: who can sign contracts, who carries liability, how you're taxed, and whether you can bid for public and hospital tenders. This article is the upper-funnel decision map. Once the mode is chosen, sales channels & market access is where the selling actually happens.
Choose how you enter before you choose what you sell through. The structure decides your options, not the other way around.
They sit on a spectrum of control and commitment. More control means more cost and responsibility; less commitment means less reach.
A German distributor or agent sells your product. Fast, low fixed cost, local relationships from day one — but you hand over margin, data and control of the customer.
A registered branch of your foreign company — a local presence without a separate legal entity. More visible and credible than a distributor, lighter than a subsidiary.
Your own German limited company. Full control, own hiring, liability ring-fenced, and the strongest basis for tenders and regulatory roles — at the highest setup and running cost.
The mode falls out of a handful of honest answers — not of what's cheapest today.
A quick read across the trade-offs that matter most.
| Dimension | Distributor | Branch | GmbH |
|---|---|---|---|
| Control | Low | Medium | Full |
| Speed to first sale | Fast | Medium | Slower |
| Setup & running cost | Lowest | Medium | Highest |
| Liability | Partner's | Parent company | Ring-fenced |
| Local credibility | Via partner | Good | Strongest |
| Tender access | Limited | Partial | Full |
| Fit for regulated products | Weak | Partial | Strong |
There's no universally “right” mode — only the one that fits your ambition and product. Many companies start light and convert to a GmbH as the market proves out.
In pharma, medtech and diagnostics, the structure choice isn't just commercial — it's a regulatory one.
Regulated products often require a legal presence and named responsible persons in Germany or the EU: a Stufenplanbeauftragter / QPPV for pharmacovigilance, a PRRC for medical devices, or an EU Authorised Representative for non-EU manufacturers. These roles usually sit inside a real entity, which pushes regulated companies toward a GmbH earlier than a pure distributor model would suggest. Here the “lightest” mode may simply not be available — and getting authorized is still only half the job, because authorized isn't the same as paid.
For regulated products, structure is where your compliance obligations live — not an afterthought.
Decisions in the order that avoids expensive backtracking.
Is Germany a test, a beachhead into the EU, or a core market? That answer pre-selects the mode.
Does your product force a local entity or named responsible persons? If yes, some modes drop out.
Run the five questions honestly and pick the mode that fits — not the cheapest today.
GmbH vs branch has real tax and liability consequences — see the structure & tax deep-dive.
Only now move to channels, distribution and reimbursement — the execution layer.
We help foreign life-sciences and industrial companies pick the entry mode that fits their ambition and product, and set up the structure that won't box them in later. One clear recommendation, with the reasoning behind it.